tiprankstipranks
Advertisement
Advertisement

CHRO Stock Latest News

Roche announces EMA’s CHMP recommended approval of Susvimo
The FlyRoche announces EMA’s CHMP recommended approval of Susvimo
2h ago
CHRO
Roche receives FDA 510(k) clearance for cobas BV/CV assay
PremiumThe Fly
Roche receives FDA 510(k) clearance for cobas BV/CV assay
2h ago
CHRO
Roche confirms FY26 outlook
PremiumThe Fly
Roche confirms FY26 outlook
1d ago
CHRO
Roche reports 1H group sales CHF 30.4B vs. CHF 30.9B last year
PremiumThe Fly
Roche reports 1H group sales CHF 30.4B vs. CHF 30.9B last year
1d ago
CHRO
Trump Trade: U.S. to impose 100% tariff on imported generic drugs
PremiumThe Fly
Trump Trade: U.S. to impose 100% tariff on imported generic drugs
2d ago
XE
AAL
Trump to set 100% tariff on generic drugs brought into U.S. starting in 2028
PremiumThe FlyTrump to set 100% tariff on generic drugs brought into U.S. starting in 2028
3d ago
AZN
BMY
MaxCyte enters technology license partnership with Genentech
Premium
The Fly
MaxCyte enters technology license partnership with Genentech
3d ago
CHRO
MXCT
Roche names Dan Malarek as President and CEO of Roche Diagnostics North America
Premium
The Fly
Roche names Dan Malarek as President and CEO of Roche Diagnostics North America
4d ago
CHRO
Genentech granted priority review for Gazyva sBLA by FDA
PremiumThe Fly
Genentech granted priority review for Gazyva sBLA by FDA
9d ago
CHRO
Nurix Therapeutics price target raised to $34 from $32 at Truist
PremiumThe Fly
Nurix Therapeutics price target raised to $34 from $32 at Truist
14d ago
CHRO
NRIX
Nurix Therapeutics price target raised to $33 from $30 at RBC Capital
PremiumThe Fly
Nurix Therapeutics price target raised to $33 from $30 at RBC Capital
14d ago
CHRO
NRIX
Roche receives CE Mark for blood test to identify tuberculosis infection
PremiumThe Fly
Roche receives CE Mark for blood test to identify tuberculosis infection
15d ago
CHRO
Roche downgraded to Hold from Buy at HSBC
PremiumThe FlyRoche downgraded to Hold from Buy at HSBC
18d ago
CHRO
Genentech announces Krascendo 1 study met primary, key secondary endpoint
Premium
The Fly
Genentech announces Krascendo 1 study met primary, key secondary endpoint
22d ago
CHRO
AI Daily: Amazon’s AWS commits $1B toward new unit
Premium
The Fly
AI Daily: Amazon’s AWS commits $1B toward new unit
24d ago
AZN
BMY
Anthropic takes aim at pharma industry with Claude Science, STAT reports
PremiumThe Fly
Anthropic takes aim at pharma industry with Claude Science, STAT reports
24d ago
AZN
BMY
Genentech announces priority review for Enspryng
PremiumThe Fly
Genentech announces priority review for Enspryng
24d ago
CHRO
Roche announces launch of AXELIOS 1, a next-gen sequencing platform
PremiumThe Fly
Roche announces launch of AXELIOS 1, a next-gen sequencing platform
25d ago
CHRO
Sanofi investors likely to view new R&D head as a positive, says BofA
PremiumThe Fly
Sanofi investors likely to view new R&D head as a positive, says BofA
1M ago
SNY
CHRO
Nurix Therapeutics price target raised to $33 from $26 at Baird
PremiumThe FlyNurix Therapeutics price target raised to $33 from $26 at Baird
1M ago
CHRO
NRIX
Genentech says FDA accepts sBLA for for Lunsumio VELO
Premium
The Fly
Genentech says FDA accepts sBLA for for Lunsumio VELO
1M ago
CHRO
FDA approves generic of Genentech’s Xofluza tablets
Premium
The Fly
FDA approves generic of Genentech’s Xofluza tablets
1M ago
CHRO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >